Greenwood Capital Associates LLC Has $381,000 Stake in Clovis Oncology Inc (CLVS)
Greenwood Capital Associates LLC lifted its position in Clovis Oncology Inc (NASDAQ:CLVS) by 21.6% in the fourth quarter, HoldingsChannel reports. The firm owned 5,605 shares of the biopharmaceutical company’s stock after purchasing an additional 996 shares during the quarter. Greenwood Capital Associates LLC’s holdings in Clovis Oncology were worth $381,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Capital Analysts LLC purchased a new stake in shares of Clovis Oncology in the third quarter worth $111,000. Phocas Financial Corp. purchased a new stake in shares of Clovis Oncology in the second quarter worth $112,000. Cypress Capital Management LLC WY increased its stake in shares of Clovis Oncology by 272.7% in the third quarter. Cypress Capital Management LLC WY now owns 2,050 shares of the biopharmaceutical company’s stock worth $169,000 after purchasing an additional 1,500 shares in the last quarter. Commonwealth Equity Services Inc purchased a new stake in shares of Clovis Oncology in the third quarter worth $239,000. Finally, First Republic Investment Management Inc. purchased a new stake in shares of Clovis Oncology in the third quarter worth $251,000.
In other Clovis Oncology news, insider Gillian C. Ivers-Read sold 3,000 shares of the stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $59.16, for a total transaction of $177,480.00. Following the completion of the transaction, the insider now owns 183,571 shares in the company, valued at $10,860,060.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Thorlef Spickschen sold 4,500 shares of the stock in a transaction on Monday, January 8th. The shares were sold at an average price of $64.97, for a total transaction of $292,365.00. Following the transaction, the director now owns 21,118 shares of the company’s stock, valued at approximately $1,372,036.46. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 18,000 shares of company stock valued at $1,123,425. 12.50% of the stock is owned by company insiders.
CLVS has been the subject of a number of analyst reports. Zacks Investment Research raised shares of Clovis Oncology from a “hold” rating to a “buy” rating and set a $95.00 price objective for the company in a research note on Tuesday, October 17th. Oppenheimer reissued a “hold” rating on shares of Clovis Oncology in a research note on Tuesday, October 10th. BidaskClub upgraded shares of Clovis Oncology from a “strong sell” rating to a “sell” rating in a research report on Saturday, December 9th. Credit Suisse Group set a $86.00 target price on shares of Clovis Oncology and gave the stock a “buy” rating in a research report on Thursday, January 18th. They noted that the move was a valuation call. Finally, JPMorgan Chase & Co. restated a “buy” rating on shares of Clovis Oncology in a research report on Thursday, January 11th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $90.43.
About Clovis Oncology
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.
Want to see what other hedge funds are holding CLVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clovis Oncology Inc (NASDAQ:CLVS).
Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.